Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. April 2025 07:57 ET | Quelle: ZyVersa Therapeutics

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

Inflammasome inhibitors have moved into P2 trials based on preclinical/P1 safety data & promising signals of efficacy. Data read-outs expected beginning H1
20. November 2024 07:55 ET | Quelle: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
17. Oktober 2024 07:50 ET | Quelle: ZyVersa Therapeutics

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.